Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
85
datasets available to search
ShareScore release 0.9.0
Dataset results
85 results for “overall survival”
Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival"
<p>Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival "</p> <p> </p> <p>Abstract</p> <p><strong>Background: </strong>It is unclear whether invasive intraductal papillary mucinous neoplasm (IPMN) has different clinical and prognostic characteristics, beyond histological factors, when compared to pancreatic ductal adenocarcinoma (PDAC).</p> <p><strong>Aims: </strong>compare prognostic features of resected PDAC and invasive IPMN METHODS: A retrospective study of patients resected for PDAC or invasive IPMN realized at Humanitas Cancer Center's Pancreatic Surgery Unit, Milan, Italy, between 2010 and 2016. Data recorded included patient demographics, onset symptoms, preoperative health status, tumor features, histology and surgical characteristics. Overall survival was estimated using Kaplan-Meier and prognostic factors for survival were assessed by multivariate Cox regression.</p> <p><strong>Results: </strong>A total of 332 patients were included (PDAC, n = 289; invasive IPMN, n = 43). Patients with invasive IPMN had better overall survival than PDAC patients (median: 76.6 versus 25.6 months; 5-year OS rate: 65.4% vs. 14.2%; p < 0.001). PDAC histology was associated with a significantly higher risk of death than IPMN (hazard ratio 1.815, 95% CI: 1.02, 3.24; p = 0.044). Survival was also worse with PDAC in early-stage disease (IA-IB-IIA, N0). In multivariate analysis, independent predictors of worse survival included perineural invasion, preoperative ASA physical status ≥3 and pain at diagnosis.</p> <p><strong>Conclusions: </strong>Patients with IPMN had a better prognosis than PDAC patients, regardless of disease stage.</p>
Dataset related to article "Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy "
<p>This record contains raw data related to article “Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy"</p> <p>Abstract:</p> <p><strong>Background: </strong> to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT).</p> <p><strong>Material and methods: </strong> Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score.</p> <p><strong>Results: </strong> 997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.</p> <p><strong>Conclusion: </strong> moving from easily accessible clinical parameters, a score was created to help the physician's decision about the better treatment or combination of treatments for the individual patient.</p>
Clinical Dataset for Risk Factors for Overall Survival in Hospitalized Adults Receiving Total Parenteral Nutrition: A Retrospective Cohort Study at a Social Security Hospital in Peru: January 2022 – June 2023
<p>This Excel dataset contains de-identified clinical data collected over a two-year period, aimed at evaluating risk factors associated with 90-day mortality in hospitalized patients receiving total parenteral nutrition (TPN). The dataset includes variables such as age, sex, clinical diagnosis, comorbidities, days in the ICU, days receiving TPN, laboratory values (lymphocytes, platelets, TGP), and the presence of acute kidney injury (AKI) or chronic kidney disease (CKD).</p> <p>The data is structured in rows, with each row representing an individual patient, and columns corresponding to the various clinical and laboratory parameters. It was used to perform survival analysis using Cox proportional hazards models and other statistical techniques. Sensitive information has been removed to ensure patient confidentiality.</p> <p>Access to the dataset is restricted, and permission must be requested for its use in further research.</p> <p><strong>File format:</strong> Excel (.xlsx)<br><strong>Keywords:</strong> Total Parenteral Nutrition, 90-Day Mortality, Risk Factors, Clinical Dataset, Cox Regression</p>
Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS)
<p>Raw annonymized data, OncoScan CEL files of the manuscript.</p> <p>PMID: 27775850</p> <p>DOI: 10.1111/his.13106</p> <p>ABSTRACT:</p> <p><strong>Aims: </strong> We aimed to define the clinicopathological characteristics of 29 primary sinonasal diffuse large B cell lymphoma (DLBCL<sup>sn</sup> ) in a series of 240 cases of DLBCL not otherwise specified [DLBCL<sup>all (</sup><sup>NOS</sup><sup>)</sup> ], including DLBCL<sup>sn</sup> training set (n = 11) and validation set (n = 18), and DLBCL<sup>non-sn</sup> (n = 211).</p> <p><strong>Methods and results: </strong> In the training set, 82% had a non-germinal center B-cell-like (Hans' Classifier) (non-GCB) phenotype and 18% were Epstein-Barr virus-encoded small RNAs (EBER)<sup>+</sup> . The genomic profile showed gains<sup>(+)</sup> of 1q21.3q31.2 (55%), 10q24.1 (46%), 11q14.1 (46%) and 18q12.1q23 (46%); losses<sup>(-)</sup> of 6q26q27 (55%) and 9p21.3 (64%); and copy number neutral loss of heterozygosity (LOH) (acquired uniparental disomy, UPD) at 6p25.3p21.31 (36%). This profile is comparable to DLBCL<sup>NOS</sup> (GSE11318, n = 203.) and closer to non-GCB/activated B-cell-like subtype (ABC). Nevertheless, +1q31, -9p21.3 and -10q11.1q26.2 were more characteristic of DLBCL<sup>sn</sup> (P < 0.001). Array results were verified successfully by fluorescence in situ hybridization (FISH) on +1q21.3 (CKS1B), -6q26 (PARK2), +8q24.21 (MYC), -9p21.3 (MTAP, CDKN2A/B), -17p13.1 (TP53) and +18q21.33 (BCL2) with 82-91% agreement. Minimal common regions included biologically relevant genes of MNDA (+1q23.1), RGS1 and RGS13 (+1q31.2), FOXP1 (+3p13), PRDM1 (BLIMP1) and PARK2 (-6q21q26), MYC (+8q24.21), CDKN2A (-9p21.3), PTEN (-10q23.31), MDM2 (+12q15), TP53 (-17p13.1) and BCL2 (+18q21.33). Correlation between DNA copy number and protein immunohistochemistry was confirmed for RGS1, RGS13, FOXP1, PARK2 and BCL2. The microenvironment had high infiltration of M2-like tumour associated macrophages (TAMs) and CD8<sup>+</sup> T lymphocytes that associated with higher genomic instability. The DLBCL<sup>sn</sup> validation set confirmed the clinicopathological characteristics, all FISH loci and immunohistochemistry (IHC) for RGS1. RGS1, one of the most frequently altered genes, was analysed by IHC in DLBCL<sup>all</sup> and high RGS1 expression associated with non-GCB, EBER<sup>+</sup> and unfavourable overall survival (hazard ratio = 1.794; P = 0.016).</p> <p><strong>Conclusions: </strong> DLBCL<sup>sn</sup> has a characteristic genomic profile. High RGS1 IHC expression associates with poor overall survival in DLBCL<sup>all (</sup><sup>NOS</sup><sup>)</sup> .</p>
Dataset related to article "Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer"
<p>This record contains raw data related to article “Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer"</p> <p>Abstract</p> <p>In recent years, immunohistochemical protein expression was studied as a surrogate to the molecular classification of bladder cancer, although no tissue biomarkers are available for clinical use to predict survival or the response to neoadjuvant chemotherapy (CT) in UC, as the literature produced conflicting results. This retrospective study included TURB specimens harboring foci of HG pT2 muscle-invasive bladder carcinoma (MIBC) from 251 patients who subsequently underwent radical cystectomy. We performed immunohistochemical analysis on tumor samples, for relevant gene-expression-based markers for basal type (<em>CD44</em>, <em>CK5/6</em>) and luminal type (<em>CK20</em> and <em>pPARγ</em>). Piescore, investigated in both non-muscle-invasive (NMI) and muscle-invasive (MI) components of the tumor, divided basal and luminal UC-types when at least three of the four markers were consistent with a specific phenotype, mixed types if one/two luminal and basal markers were present simultaneously, and neu-like types when all four markers investigated were negative. Eighteen selected cases were also investigated with RT-PCR to validate, and to increase the specificity of, the immunohistochemical results. We observe an immunophenotypical difference in the NMI and MI components in 96/251 UC patients (38.25%): half of tumors (44/96 cases) have a transition to basal, 36.46% (35/96 cases) to neu-like, 12.5% (12/96 cases) to mixed, and 5.2% (5/96 cases) to luminal phenotypes. Mixed tumors in the NMI component are more likely to change phenotype than other groups, particularly compared with basal tumors, which demonstrate greater stability (only 8/96 cases, <em>p</em> &lt; 0.00001). The transition of luminal tumors to basal display a better OS compared with the transition toward neu-like tumors (<em>p</em> = 0.027). Overall, the phenotypical switch does not affect lymphovascular invasion, pT, DFS, or OS compared with non-switched cases. In the MI component, the presence of <em>CD44</em> expression, irrespective of score-related phenotype, shows a protective effect in papillary-type UC (OS <em>p</em> = 0.008, HR 0.453, PFS <em>p</em> = 0.07, HR 0.599), and in UC naïve for CT (<em>p</em> = 0.0479). Piescore immunophenotyping reveals an intratumoral phenotypical transition between the NMI and MI components of the same tumor. The molecular change is a common event in the mixed and luminal categories, but not in basal tumors, which show better phenotypical stability. This phenomenon could partially explain the sensitivity of a subset of luminal UC to chemotherapy: good responders could be "non-real" luminal UC, which acquire nasal markers, such as <em>CD44</em>.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.